Phase IIa Study to Characterize the Effects of the Spiegelmer NOX H94 on Anemia of Chronic Disease in Patients With Cancer

Trial Profile

Phase IIa Study to Characterize the Effects of the Spiegelmer NOX H94 on Anemia of Chronic Disease in Patients With Cancer

Completed
Phase of Trial: Phase II

Latest Information Update: 30 Jun 2017

At a glance

  • Drugs Lexaptepid pegol (Primary)
  • Indications Anaemia
  • Focus Therapeutic Use
  • Sponsors NOXXON Pharma AG
  • Most Recent Events

    • 24 Apr 2014 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top